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Main findings  
Targeted pre-emptive fluconazole initiated at 800 mg/day following post-screening lumbar 
puncture to exclude underlying cryptococcal meningitis in blood cryptococcal antigen (CrAg)-
positive asymptomatic patients starting antiretrovirals at less than 100 CD4 cells/μL, 
significantly reduces incidence of CM and has some survival benefits.  
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Abstract 
Cryptococcal antigen (CrAg) screening and targeted pre-emptive fluconazole in antiretroviral 
naive HIV-infected adults with less than 100 CD4 cells/μL seems promising to reduce the 
burden of cryptococcal meningitis (CM). We searched MEDLINE, EMBASE, and Web of 
Science and used random-effect meta-analysis to assess the prevalence of blood CrAg-
positivity (31 studies; 35,644 participants) and asymptomatic CM in CrAg-positives, incidence 
of CM and all-cause mortality in screened participants. Pooled prevalence of blood CrAg-
positivity was 6% (95%CI: 5 – 7) and asymptomatic CM in CrAg-positives was 33% (95%CI: 
21 – 45). Incidence of CM without pre-emptive fluconazole was 21.4% (95%CI: 11.6 – 34.4) 
and 5.7% (95%CI: 3.0 – 9.7) with pre-emptive fluconazole initiated at 800 mg/day. In CrAg-
positives, post-screening lumbar puncture prior to initiating pre-emptive fluconazole at 800 
mg/day further reduced incidence of CM to null and showed some survival benefits. However, 
all-cause mortality remained significantly higher in CrAg-positives than CrAg-negatives: RR: 
2.2 (95%CI: 1.7 – 2.9, p<0.001).  
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INTRODUCTION  
Cryptococcal meningitis (CM) is due to a ubiquitous environmental encapsulated yeast, 
Cryptococcus spp, and occurs primarily in patients with advanced defective cell-mediated 
immunity [1, 2]. Consequent to the HIV pandemic, there has been a remarkable surge in the 
incidence of CM, especially in Sub-Saharan Africa [3, 4]. In such settings, over 90% of CM 
occur in HIV-infected patients [5, 6]. With the introduction of antiretroviral therapy (ART) in 
the 1990s, the incidence of CM has declined in high-income countries (HIC) [7, 8]. However, 
in low- and middle-income countries (LMIC), around 20% of patients still present to HIV care 
with less than 100 CD4 cells/μL, a major risk factor for developing CM [4, 9]. In LMIC settings, 
CM accounts for around 15% of HIV-related mortality [4] with in-hospital case fatality rates 
ranging between 30 – 60% in recent Sub-Saharan African cohorts [6, 10-13]. 
There is therefore urgent need for effective preventive strategies to reduce the burden of CM 
[14]. The “blanket” strategy no longer recommended, relied on fluconazole-based primary 
prophylaxis in all patients with less than 100 CD4 cells/μL [15]. Though this strategy was 
shown to reduce the incidence of CM [16], it was not widely implemented because of lack of 
evidence on survival benefits, potential for inducing resistance to fluconazole and high cost. 
This prompted experts to suggest targeted pre-emptive fluconazole therapy to patients 
identified at higher risk of CM who are more likely to benefit from this pre-emptive treatment 
[17].  
Cryptococcus contains a capsular polysaccharide, known as cryptococcal antigen (CrAg), 
which can be detected in blood weeks to months prior to onset of CM [18]. Evidence suggests 
that without fluconazole therapy, CrAg-positive patients have up to 25% risk of CM in the first 
year of ART [14, 19]. Thus, in 2011, the World Health Organisation (WHO) suggested routine 
CrAg screening in ART-naïve HIV-infected adults with less than 100 CD4 cells/μL, using 
either latex agglutination (LA) or lateral flow assay (LFA) procedures [20] (LFA easier and 
results obtained within ten minutes [21]). Following WHO’s advice, CrAg-positive patients 
without meningitis should be offered pre-emptive oral fluconazole at a tapering dose of 800 
mg/day for two weeks, then 400 mg/day for eight weeks, followed by 200 mg/day until control 
CD4 is above 200 cells/μL [20]. Nonetheless, this recommended dosage remains provisional 
because the optimal antifungal regimen for this population is not clearly established [22].  
CrAg screening with targeted pre-emptive fluconazole therapy seems attractive and cost-
effective [23-26], but how best to implement it in overstretched, under-resourced high disease 
burdened health care settings remains a challenge. Nevertheless, it is incorporated into several 
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national HIV care guidelines, both in LMIC (Botswana, Kenya, Mozambique, Namibia, 
Rwanda, South Africa, Swaziland, Uganda) and HIC settings (USA and France) [4, 27]. 
Though promising, a systematic assessment of the impact of this strategy is lacking. We 
therefore performed a systematic review and meta-analysis (SRMA) to assess four key clinical 
outcomes of routine CrAg screening and targeted pre-emptive fluconazole therapy in ART-
naïve HIV-infected adults with less than 100 CD4 cells/μL: the prevalence of CrAg positivity, 
the prevalence of asymptomatic CM in CrAg-positives, the incidence of CM and all-cause 
mortality during follow-up in screened participants. 
METHODS 
Search strategy and study selection  
A medical information specialist (RS) developed a comprehensive search strategy to identify 
published and unpublished studies in MEDLINE, EMBASE, and Web of Science. Medical 
subject headings (MeSH) and keywords included: “cryptococcal antigen”, “cryptococcal 
surface polysaccharides”, “cryptococcal meningitis”, “HIV”, “screening”, “detection”, “latex 
agglutination”, “lateral flow assay” (Supplementary Table 1). To avoid missing relevant 
studies, we did not use methodological filters. Searches were run from January 1981 (year of 
first HIV case) through April 2018. References of included studies and previous reviews on 
the subject were screened for eligibility. Reports that cited included studies were also searched 
on Google Scholar. Conference proceedings of the Conference on Retroviruses and 
Opportunistic Infections (CROI), the International Conference on Cryptococcus and 
Cryptococcosis (ICCC), and the International AIDS Society (IAS) conference were screened 
from 2010 onwards. 
Two review authors (ET, JJB) independently screened studies by title and abstract and assessed 
full texts of potentially relevant studies. Discrepancies were discussed and when consensus was 
not reached, study inclusion was further discussed with a third author (JFC). Study selection 
was done using Rayyan systematic reviews online application (http://rayyan.qcri.org).  
We included cross-sectional studies, randomised controlled trials (RCT), and cohort studies 
(retrospective and prospective) in which study participants were screened for CrAg using LA 
or LFA procedures. Case-control studies and case reports were excluded. Study participants 
had to be HIV-infected adults (age >18 years) presenting to HIV-care programs with less than 
100 CD4 cells/μL, naïve to ART, with no symptoms suggestive of CM, in whom serum CrAg 
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screening was done prior to ART initiation. There was no country restriction. Only studies 
published in English, French and Spanish were included.  
In this review, the main intervention of interest was pre-emptive fluconazole therapy in CrAg-
positive patients. However, to the best of our knowledge, there is no RCT evaluating the 
effectiveness of this intervention. A placebo-controlled trial would be unethical because there 
is enough clinical evidence to suggest that fluconazole therapy may reduce the risk of CM in 
severely immunosuppressed HIV-infected patients [16]. Consequently, in the present review, 
the impact of this intervention was evaluated based on observational studies. 
Our clinical outcomes of interest were: (i) the prevalence of blood (serum/plasma) CrAg 
positivity in screened participants, (ii) the prevalence of asymptomatic CM (ascertained by 
positive fungal culture and/or Indian ink staining and/or CrAg in cerebrospinal fluid [CSF]) in 
blood CrAg-positive patients, (iii) the incidence of CM during follow-up, and (iv) all-cause 
mortality during follow-up.  
Data extraction and quality assessment  
For each study, we extracted: 
 Study characteristics: first author, publication year, design (RCT, cohort, cross-sectional), 
country; 
 Participant characteristics: total number, proportion of ART-naïve, number with less than 
100 CD4 cells/μL; 
 CrAg screening test procedure: LA or LFA;  
 CrAg screening outcome: number screened, number and proportion of CrAg-positive  
 Interventions offered to CrAg-positive patients: lumbar puncture (number of confirmed 
asymptomatic CM), pre-emptive fluconazole therapy (offered or not, number of 
participants offered fluconazole, initial dose offered, duration), ART (median time to 
initiation if available); 
 Clinical outcomes within follow-up: incidence of CM (number and proportion in CrAg-
positive and CrAg-negatives), all-cause mortality (number and proportion in CrAg-
positive and CrAg-negatives), number lost to follow-up within each group, if reported;  
We assessed risk of bias only in studies where screened patients were subsequently followed 
up. For this, we adapted a quality assessment tool (Supplementary Table 2) based on the Joanna 
Briggs Institute checklist for cohort studies [28]. The main components of the review question 
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considered were: study population (HIV-infected adults with less than 100 CD4 cells/μL), 
exposure (CrAg status and the method used to determine it), intervention (targeted pre-emptive 
fluconazole therapy or not, ART to screened patients), and the outcomes of interest during 
follow-up (incidence of CM and all-cause mortality). For each study, we assessed patient 
selection bias, treatment allocation bias, outcome assessment bias and completeness of 
outcome data bias. Where insufficient information was reported we contacted study authors for 
clarification. 
Data analysis  
Data were pooled using standard random-effects meta-analysis for proportions using the 
Freeman-Tukey double arcsine transformation and the metaprop command [29] in STATA 
15.0 (Statacorp, Texas, USA) to estimate the prevalence of CrAg positivity in screened 
participants and the prevalence of asymptomatic CM in CrAg-positive participants, and 
reported with their 95% confidence interval (95%CI).  
In studies where screened participants were subsequently followed up, random-effects models 
were used in Review manager (Revman) version 5.3 [30] to estimate the incidence of CM and 
all-cause mortality during follow-up as well as risk ratios (RR) comparing CrAg-positive to 
CrAg-negative participants. This analysis was stratified by the type of interventions offered to 
CrAg-positive participants (i.e., no pre-emptive fluconazole, pre-emptive fluconazole initiated 
at <800 mg/day or 800 mg/day or initiated at 800 mg/day following post-screening lumbar 
puncture).  
Heterogeneity was evaluated graphically by observing forest plots and by calculating I² 
statistics. Additional stratified analysis was performed to explore heterogeneity when I² was 
greater than 50%.  
The protocol was registered in the PROSPERO international prospective register of systematic 
reviews, registration number CRD42018087608. 
RESULTS  
The electronic search ran on April 20th, 2018 identified 2,115 citations (314 duplicates). Based 
on title and abstract screening, 1,741 citations were excluded (Figure 1). On further assessment 
of 60 citations, 29 more were excluded. A total of 31 studies were included for estimating the 
prevalence of CrAg positivity [14, 22, 23, 26, 31-57], of which ten to evaluate the prevalence 
of asymptomatic CM in CrAg-positive participants [31, 33, 40, 41, 45, 48, 50, 51, 55, 57], four 
to evaluate the incidence of CM and all-cause mortality in the context of no fluconazole pre-
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emptive therapy [14, 32, 35, 49], and twenty to evaluate the incidence of CM and/or all-cause 
mortality in the context of pre-emptive fluconazole therapy [14, 22, 23, 32, 33, 35, 39-45, 48-
51, 53, 55, 56]. The quality of included studies is summarised in Supplementary text and 
Supplementary Figure 1. 
Prevalence of blood CrAg positivity and asymptomatic CM in CrAg-positives 
Thirty-one studies from 22 countries (67.7% Sub-Saharan African) were included [14, 22, 23, 
26, 31-57] of which 22 (71%) cohorts, 3 (9.7%) randomised trials, and 6 (19.4%) cross-
sectional (Table 1). In these, 38,383 participants underwent CrAg screening irrespective of CD4 
count, of whom 35,644 (92.9%) had less than 100 CD4 cells/μL (our target population). 
Screening was done with LFA in 20 (64.5%) studies, and LA in the rest. Screening was 
performed in real-time on fresh sera in 20 (64.5%) studies and retrospectively on stored sera in 
11 (35.5%). In participants with >100 CD4 cells/μL, the median prevalence of CrAg positivity 
was 2% (Interquartile range [IQR]: 1 – 3). In those with <100 CD4 cells/μL, CrAg positivity 
ranged from 0 - 21% and pooled prevalence was 6% (95%CI: 5 – 7; I2 = 89.3%) (Figure 2). 
Pooled CrAg prevalence was slightly higher with LA than LFA: 8% (95%CI: 5 -11; I2 = 
90.34%) vs 5% (95%CI: 4 – 6, I2 = 88.9%), p = 0.13, respectively; in prospective than 
retrospective cohorts: 6% (95%CI: 5 – 8, I2 = 83.8%) vs 5% (95%CI: 3 – 8, I2 = 87.6%), p = 
0.78 and in fresh than stored sera: 7% (95%CI: 5 – 9, I2 = 89.9%) vs 6% (95%CI: 5 – 7, I2 = 
76.4%), p = 0.02, respectively (Supplementary Figures 2 and 3).  
Following CrAg screening, lumbar puncture (LP) was offered to CrAg-positive participants 
(who presented no symptoms of CM) in 10 studies [31, 33, 40, 41, 45, 48, 50, 51, 55, 57]. 
Among the 403 participants eligible for LP, 276 (68.5%) accepted and the pooled prevalence 
of confirmed asymptomatic CM in CrAg-positives was 33% (95%CI: 21 – 45; I2 = 76.1%); 
Figure 3. 
Incidence of cryptococcal meningitis 
During the median follow up of 1-year (IQR: 0.5 – 1), when CrAg-positive participants were 
not offered pre-emptive fluconazole, incidence of CM was 21.4% (95%CI: 11.6 – 34.4) vs 
0.4% (95%CI: 0.1 – 1) in CrAg-negatives (Table 2, Figure 4.1).  
When pre-emptive fluconazole was offered to CrAg-positives, stratifying by initial dose, less 
than 800 mg/day was associated with more incident cases of CM than 800 mg/day: 9.1% 
(95%CI: 2.5 – 21.7) vs 5.7% (95%CI: 3.0 – 9.7), Figure 4.2. In these analyses, incidence was 
consistently less than 1% in CrAg-negatives (Table 2). Moreover, performing LP to CrAg-
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positive participants to exclude those with confirmed asymptomatic CM prior to initiating pre-
emptive fluconazole at 800 mg/day significantly reduced the incidence of CM to similar levels 
in CrAg-negatives: 0% (95%CI: 0 – 0.8) and 0.4% (95%CI: 0 – 1), p = 0.12, respectively and 
this was independent of CrAg test used (Supplementary figure 4.1). 
Incidence of all-cause mortality 
Following CrAg screening, when no pre-emptive fluconazole was offered to CrAg-positives, 
incidence of all-cause mortality during follow-up was significantly higher than in CrAg-
negatives: 39.7% (95%CI: 28.8 – 51.5) vs 13.9% (95%CI: 11.8 – 16.2), respectively (Table 3, 
Figure 5.1). Offering pre-emptive fluconazole at 800 mg/day was associated with decreased 
mortality risk in CrAg-positives compared to no fluconazole: 17.4% (95%CI: 13.9 – 21.4). 
Nevertheless, incidence of all-cause mortality remained significantly higher in CrAg-positives 
than in CrAg-negatives even after excluding CrAg-positives with asymptomatic CM prior to 
initiating fluconazole at 800 mg/day, RR: 2.2 (95%CI: 1.7 – 2.9, p<0.001) (Table 3, Figure 
5.3), independent of CrAg test used (Supplementary figure 4.2)  
DISCUSSION 
Main findings  
This SRMA shows that (i) the prevalence of CrAg positivity in asymptomatic HIV-infected 
patients with less than 100 CD4 cells/μL is around 6% [4, 58], (ii) among CrAg-positives, the 
prevalence of asymptomatic CM is approximately 30%, (iii) the incidence of CM in CrAg-
positives drops from around 20% without pre-emptive fluconazole to 5% with pre-emptive 
fluconazole initiated at 800 mg/day, (iv) initiating pre-emptive fluconazole at 800 mg/day after 
excluding asymptomatic CM reduced overall mortality in CrAg-positives from around 40% to 
around 20%, but CrAg-positives still had more than two-fold risk of death than CrAg-
negatives. 
Implications for practice  
Our findings show that targeted pre-emptive fluconazole initiated at 800 mg/day may reduce 
the incidence of CM from around 20% to around 5%, thus strong evidence of its effectiveness. 
Furthermore, when CrAg-positive patients were offered post-screening lumbar puncture, the 
incidence of CM even reduced further to less than 1%, which is comparable to that observed 
in CrAg-negatives. This supports systematically offering LP to CrAg-positives to prevent 
clinically asymptomatic patients with CSF evidence of meningitis from receiving sub-optimal 
induction antifungal treatment with fluconazole monotherapy, known to be less effective in 
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CM even at highest dosages [59, 60]. In other words, the observed incident CM cases during 
follow-up despite pre-emptive fluconazole therapy might be a resultant of insufficient 
treatment and unmasking secondary to immune reconstitution inflammatory syndrome [61]. 
We therefore suggest that the objective is not only to identify CrAg-positive patients, but also, 
among them, those who have asymptomatic CM. Patients with asymptomatic CM should be 
treated with recommended induction antifungal combination therapy: one-week Amphotericin 
B plus flucytosine or oral high dose fluconazole plus flucytosine [62], while fluconazole pre-
emptive therapy should be restricted to those without CSF evidence of CM. 
In studies reporting the experience of routine CrAg screening and targeted fluconazole therapy 
in LMIC settings, we found little heterogeneity, suggesting similarities across these studies in 
the overall implementation of the CrAg screen-and-treat strategy: tests used, classification of 
patients as CrAg-positives or -negatives, fluconazole to CrAg-positive patients, post-screening 
ART initiation, follow-up and reporting of ascertained CM cases over time. However, there 
was much variability in the way fluconazole was offered to CrAg-positive patients in terms of 
dosage and duration. Few studies provided fluconazole at the WHO-suggested tapering dose 
and duration [40, 42, 43, 45, 48, 51-53, 55]. In some, fluconazole was initiated at 800 mg/day 
and provided for four weeks only [41] or for two weeks then 400 mg/day for another two weeks 
and stopped [22]; these short courses seemed to be due to local realities of insufficient 
fluconazole availability. This shows that for targeted pre-emptive therapy to be effective as a 
preventive strategy for CM, readily available and sustainable fluconazole is a prerequisite, 
especially as CrAg point-of-care tests are becoming more available [21, 63] and accepted by 
clinicians and patients.  
Implications for research  
Given that most studies show moderate lumbar puncture feasibility and acceptance (68.5%), 
there is critical need for more acceptable methods for identifying those with asymptomatic CM 
among CrAg-positives. With existing evidence of association between serum CrAg titres and 
asymptomatic CM [43, 45, 55, 57, 64], systematic per-screening CrAg quantification can be 
done, and a threshold defined beyond which patients could be considered for recommended 
inductive combination antifungal therapy [62]. Available evidence suggests such a threshold 
is around 1:160 [45, 55, 57, 64] and a recent Ugandan study [43] showed strong association 
between this titre level and incident CM within weeks of ART initiation. Future research should 
aim at evaluating whether semi-quantitative point-of-care CrAg tests [55, 63] capable of 
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identifying patients with high titres [65] would increase the effectiveness of pre-emptive 
therapy. 
With regards to the effect of targeted pre-emptive therapy on all-cause mortality, we found 
some evidence that initiating fluconazole at 800 mg/day in CrAg-positive patients exempt of 
asymptomatic CM may have some benefits on mortality during the first year of ART initiation. 
However, mortality was still significantly higher than in CrAg-negative patients suggesting the 
existence of poorly understood non-CM CrAg status-related mortality predispositions worthy 
of further exploration. Perhaps, following ART initiation, CrAg positivity may affect immune 
response to other opportunistic infections leading to death. Further research could therefore 
focus on quality of immune responses following ART initiation, comparing CrAg-positives to 
CrAg-negatives.  
Study limitations  
Our study has some limitations. The effect of pre-emptive fluconazole on the incidence of CM 
and all-cause mortality in CrAg-positive patients was indirectly evaluated because most of the 
included studies were observational with very few RCTs. Even the included RCTs, none was 
randomised to compare pre-emptive fluconazole to no fluconazole or to an alternative pre-
emptive therapy in CrAg-positive patients. Consequently, we report only indirect evidence for 
the effectiveness of the WHO CrAg screen-and-treat strategy. Furthermore, not all studies 
evaluated our predefined main outcomes of interest and this resulted in variable denominators 
(number of studies and number of participants) across the outcomes. Also, the data were scarce 
for several outcomes, with zero cells leading to unstable estimates and wide confidence 
intervals. We acknowledge that effects on incidental CM cases and mortality rates during 
follow-up would have been better assessed through more reliable survival methods that account 
for censoring, but these data were not available for analysis. None of the studies addressed 
CrAg screening and pre-emptive therapy in ART-experienced patients though growing 
evidence suggests a considerable proportion of patients with advance HIV due to failing ART. 
Authors’ conclusion  
Offering fluconazole pre-emptive therapy at presently recommended doses to CrAg-positive 
patients compared to no fluconazole, substantially reduces the risk of incident CM and may 
have survival benefits. The high prevalence of asymptomatic CM in CrAg-positive patients 
together with low uptake of lumbar puncture, justifies the development of reliable point-of-
care tests capable at point of screening, of identifying CrAg-positive patients at higher risk of 
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underlying asymptomatic CM. The availability of sustainable fluconazole in ART programs is 
essential for effective pre-emptive strategies.  
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TABLES AND LEGEND OF FIGURES 
Table 1. Characteristics of included studies and outcomes assessed per study 
Author, Year Study design 
(screening) 
CrAg 
test 
Median 
follow-up 
Country N* Fluconazole pre-emptive 
therapy 
Outcomes assessed 
       CrAg 
positivity 
Asymptomatic 
CM in CrAg+ 
CM during 
follow-up 
Mortality 
during 
follow-up 
Desmet et al (1989) 
[31] 
Prospective  LA None Democratic 
Republic of 
Congo 
450 No Yes  Yes No  No 
Liechty et al (2007) 
[32] 
Retrospective  LA > 3 months Uganda 377 No Yes No Yes Yes 
Jarvis et al (2009) 
[14]  
Retrospective  LA 1 year South Africa 707  
 
No Yes  No Yes Yes 
Meya et al (2010) 
[23] 
Prospective LA 47 months Uganda 295  
 
200 - 400 mg/day for 2 - 4 
weeks 
Yes  No Yes Yes 
Pongsai et al (2010) 
[33]  
Retrospective LA 1 year Thailand 85  
 
Yes (dose not reported) Yes  Yes Yes No 
Mamoojee et al 
(2011) [34] 
Retrospective  LA Not 
reported 
Ghana 92  
 
No Yes No No No 
Linares et al (2012) 
[35] 
Retrospective  LFA 1 year Peru 365  
 
No Yes No Yes Yes 
Osazuwa et al 
(2012) [36] 
Cross-
sectional 
LA None Nigeria 81  
 
No Yes No No No 
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Smith et al (2013) 
[26] 
Retrospective LFA None Vietnam 226  
 
No Yes No No No 
Ganiem et al 
(2014) [37] 
Retrospective  LFA HIV 
diagnosis till 
incidence of 
death  
Indonesia 810 
 
No 
(primary prophylaxis: < 
200 CD4) 
Yes No No No  
Mckenney et al 
(2014) [38] 
Retrospective LFA Not reported USA 1,872 Not reported Yes No No No 
Manabe et al 
(2015) [39] 
Prospective LA > 1 year USA 117  
 
Yes (at physician’s 
discretion) 
Yes No Yes Yes 
Pac et al (2015) 
[41] 
Prospective LA 6 months Uganda 177  
 
800 mg/day for four weeks Yes Yes Yes Yes 
Kapoor et al (2015) 
[22] 
Prospective 
 
LFA 6 months Tanzania 216  
 
800 mg/day for two weeks, 
then 400mg/day for two 
weeks 
Yes No Yes Yes 
Mfinanga et al 
(2015) [40] 
Prospective LFA 1 year Tanzania and 
Zambia 
717  
 
**WHO recommended 
dose 
Yes Yes No Yes 
Chipungu et al 
(2015) [42] 
Prospective LFA 6 months Malawi 113  
 
**WHO recommended 
dose 
Yes No Yes No 
Vallabhaneni et al 
(2015) [44] 
Retrospective 
 
LA 1 year South Africa 1,170 
 
Yes (at physician’s 
discretion) 
Yes No Yes No 
Ezeanolue et al 
(2016) [46] 
Retrospective LFA Not reported Nigeria 2,752 
 
No Yes No No No 
Longley et al 
(2016) [45] 
Prospective 
 
LFA 1 year South Africa 645  
 
**WHO recommended 
dose 
Yes Yes Yes Yes 
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Morawski et al 
(2016) [43] 
Prospective LFA 1 year Uganda 2,135  
 
**WHO recommended 
dose 
Yes No Yes Yes 
Ogouyemi-Hounto 
et al (2016) [47] 
Cross-
sectional 
LFA None Benin 155 No  Yes No  No   No  
Frola et al (2017) 
[48] 
Prospective LFA 9 months  Argentina  123 **WHO recommended 
dose 
Yes  Yes  Yes  No  
Hajiabdolbaghi et 
al (2017) [49] 
Prospective LFA 6 months  Iran  86 No  Yes  No  Yes  No  
Kadam et al (2017) 
[50] 
Prospective LA 6 months  India  208 No  Yes  Yes  No  Yes  
Makadzange et al 
(2017) [51] 
Cross-
sectional  
LFA 1 year  Zimbabwe  1336 **WHO recommended 
dose 
Yes  Yes  No  Yes  
Rick et al (2017) 
[52] 
Prospective LFA 5 months  Lesotho  128 **WHO recommended 
dose 
Yes  No  No  No  
Vu et al (2017) [53] Prospective  LFA 6 months  Vietnam  944 **WHO recommended 
dose 
Yes  No  No  Yes  
Nalintya et al 
(2017) [54] 
Prospective LFA 6 months  Uganda  1,440 **WHO recommended 
dose 
Yes  No  No  No  
Temfack et al 
(2018) [55] 
Prospective  LFA 1 year  Cameroon 186 **WHO recommended 
dose 
Yes  Yes  Yes  Yes  
Thomsen et al 
(2018) [56] 
Retrospective LFA  1 year  Guinea Bissau 200 No  Yes  No  No  Yes  
Wake et al (2018) 
[57] 
Cross-
sectional  
LFA None  South Africa  19,233 **WHO recommended 
dose 
Yes  Yes  No  No  
Abbreviations: CrAg, cryptococcal antigen; LA, latex agglutination; LFA, lateral flow assay; CM, cryptococcal meningitis 
*N is number of patients except for Mckenney and Ezeanolue (number of stored samples). 
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**WHO recommended dose: 800 mg/day for two weeks, then 400 mg/day for 8 weeks followed by 200 mg/day till CD4 above 200 cells/μL 
 
Table 2. Incidence of cryptococcal meningitis during follow-up 
    
Incidence of CM during follow-up,  
% (95%CI) 
Risk ratio  
(95% CI) 
p-value 
 Interventions offered to CrAg-positive participants Number of studies N CrAg-positives CrAg-negatives   
No pre-emptive fluconazole 4 1,143 21.4 (11.6 – 34.4) 0.4 (0.1 – 0.9) 52.7 (6.4 – 431.2) 0.0002 
Any pre-emptive fluconazole 11 5,006 6.3 (3.6 – 9.9) 0.3 (0.2 – 0.5)  15.6 (4.5 – 53.8) <0.0001 
Stratified analysis  
 Pre-emptive fluconazole initiated at < 800 mg/day 4 1,635 9.1 (2.5 – 21.7) 0.6 (0.3 – 1.0) 15.9 (3.3 – 75.7) 0.0005 
 Pre-emptive fluconazole initiated at 800 mg/day 7 3,371 5.7 (3.0 – 9.7) 0.1 (0 – 0.3)  14.9 (1.9 – 111.7) 0.009 
 
Pre-emptive fluconazole initiated at 800 mg/day following 
post-screening lumbar puncture 
4 1108 0 (0 – 0.8)  0.3 (0 – 0.8)  5.7 (0.7 – 49.8)  0.12 
Abbreviations: CrAg, cryptococcal antigen; 95%CI, 95% confidence interval; N, number of participants; CM, cryptococcal meningitis. 
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Table 3. All-cause mortality rates during follow-up 
    
All-cause mortality during follow-up, 
% (95%CI) 
Risk ratio 
(95% CI) 
p-value 
 Interventions offered to CrAg-positive participants Number of studies N CrAg-positives CrAg-negatives   
No pre-emptive fluconazole 4 1099 39.7 (28.8 – 51.5) 13.9 (11.8 – 16.2) 2.6 (1.8 – 3.6) <0.00001 
Any pre-emptive fluconazole 10 6605 17.9 (14.4 – 21.8) 14.1 (13.2 – 15.0) 1.7 (1.0 – 3.0) 0.06 
Stratified analysis  
 Pre-emptive fluconazole initiated at <800 mg/day 2 395 25.9 (11.1 – 46.3) 6.5 (4.2 – 9.5) 9.4 (0.04 – 2069) 0.42 
 Pre-emptive fluconazole initiated at 800 mg/day 8 6,210 17.4 (13.9 – 21.4) 14.6 (13.7 – 15.5) 1.6 (0.9 – 2.7) 0.11 
 
Pre-emptive fluconazole initiated at 800 mg/day 
following post screening lumbar puncture 
5 3060 21.3 (16.1 – 27.3) 10.7 (9.6 – 11.9) 2.2 (1.7 – 2.9) <0.00001 
Abbreviations: CrAg, cryptococcal antigen; 95%CI, 95% confidence interval; N, number of participants; CM, cryptococcal meningitis. 
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Legend of figures. 
Legends of figures:  
Figure 1. Flow diagram of the study selection process. Abbreviations: N, number of studies; CrAg, cryptococcal 
antigen; CM, cryptococcal meningitis 
Figure 2. Prevalence of CrAg positivity in patients with less than 100 CD4 cells/μL. Abbreviations: ES, effect 
size; CI, confidence interval 
Figure 3. Prevalence of asymptomatic cryptococcal meningitis among CrAg-positive patients with less than 
100 CD4 cells/μL. Abbreviations: ES, effect size; CI, confidence interval 
Figure 4. Forest plots of incidence of cryptococcal meningitis during follow-up. Abbreviations: M-H, Mantel-
Haenszel; CI, confidence interval, LP, lumbar puncture 
Figure 5. Forest plots of incidence of all-cause mortality during follow-up. Abbreviations: M-H, Mantel-
Haenszel; CI, confidence interval, LP, lumbar puncture 
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Supplementary text: Risk of bias evaluation tool adapted from Joanna Briggs Institute 
checklist for cohort studies 
Overall, the methodological quality of the 20 studies included in the analysis of the 
effectiveness of pre-emptive fluconazole therapy vs no fluconazole and the quality 
assessment of results of each study in supplementary Figure 1. The median sample size was 
295 patients (IQR:  128 – 944). In these studies, when patient with >100 CD4 cells/ μl cells 
were also screened, only CrAg-positive patients with <100 CD4 cells/ μl were offered pre-
emptive fluconazole. In 10 (50%) of the studies, CrAg-positive patients were consented for 
post-CrAg screening lumbar puncture and in 9 of the studies, pre-emptive fluconazole was 
offered only to asymptomatic patients as clearly described in each study. In one study where 
5 CrAg-positive patients were not offered pre-emptive therapy, their outcome was clearly 
described and not included in the analysis of those who took pre-emptive fluconazole [1]. 
During the follow-up period, 11 (55%) studies reported incidence of first episode of post-
ART CM in both CrAg-positive and -negative patients but   16 (80%) reported the incidence 
of either CM or mortality only.  In one study, it was not very clear how reporting was done in 
CrAg-negative patients [1] (Supplementary Figure 1) and repeated efforts to contact study 
authors were to no avail. In 2 (10%) studies, lost to follow up was considered and reported.  
 Overall, in 27 (87.1%) studies, it was reported that all screened patients (CrAg-positives and 
-negatives) were placed on ART (deferred by 2 – 4 weeks in CrAg-positive patients) and 
followed up for a median duration of 1 year (IQR: 0.5 – 1). Adherence to ART and 
fluconazole was not evaluated in this review because they were infrequently reported in the 
included studies. 
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SUPPLEMENTS 
Supplementary table 1: MEDLINE search strategy 
# Searches 
1 exp "Antigens, Fungal"/ or exp "Clinical Laboratory Techniques"/ or exp "Point-of-
Care Systems"/ or exp "Latex Fixation Tests"/ or exp "Enzyme-Linked 
Immunosorbent Assay"/ or exp "Immunoenzyme Techniques"/mt or exp 
"Immunologic Tests"/ or exp Immunoassay/ or "Immunoenzyme Techniques"/ or exp 
Reagent Kits, Diagnostic/ or Immunochromatography/ or (Dipstick or RDT or 
(Diagnos* adj2 kit) or (antigen adj (test or detection)) or (reagent adj2 strip*) or 
(Immuno* adj2 test) or Point-of-Care Systems or ((simple or easy or quick or rapid) 
adj4 (test* or diagnos* or kit or kits)) or "latex agglutination" or "Latex particle 
agglutination" or "enzyme immunoassay*" or "enzyme immuno-assay" or "enzyme-
linked immunoassay*" or ELISA* or EIA or immunochromatograph* or lateral-flow 
or LFA or Crag).ti,ab,kf. 
2 exp "Meningitis, cryptococcal"/ or exp cryptococcosis/ or exp "Cryptococcus 
neoformans"/ or (toruloma* or cryptococc*).ti,ab,kf. 
3 exp "HIV Infections"/ or exp HIV/ or "sexually transmitted diseases, Viral"/ or (hiv* 
or "human immunodeﬁciency virus" or "human immunedeficiency virus" or "human 
immuno-deficiency virus" or "human immune-deficiency virus" or ("human immun*" 
adj2 "deficiency virus") or "acquired immunodeficiency syndrome" or "acquired 
immunedeficiency syndrome" or "acquired immuno-deficiency syndrome" or 
"acquired immune-deficiency syndrome" or ("acquired immun*" adj2 "deﬁciency 
syndrome")).ti,ab,kf. 
4 1 and 2 and 3 
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Supplementary table 2: Joanna Briggs institute cohort study quality assessment tool 
(tailored to the review question) 
The responses are either Yes (Y), No (N), unclear or N/A 
Selection bias  Y N N/A 
1. Were the two groups (CrAg positive and negative) recruited from 
the same population of patients with <100 CD4 count? 
   
Allocation bias    
1. Was CrAg screening done using the same tests in the whole study 
population? 
   
2. Was CrAg screening done using either Latex agglutination test or 
IMMY LFA? 
   
3. Were the two groups (CrAg positive and negative) similar to each 
other in baseline characteristics and other co-morbidities 
(confounders)? 
   
4. If both groups were had some identified differences, were strategies 
to deal with these differences stated in the study (stratification and 
adjustment during analysis) 
   
Outcome assessment  Y N N/A 
1. Was there baseline diagnosis of CM through lumbar punctures after 
screening to ensure both groups did not have the primary outcome 
of interest? 
   
2. During follow up, how was the incidence of CM ascertained? Was 
it by Indian ink stain or culture or CrAg in CSF?  
   
Completeness of outcome data  Y N N/A 
1. Was the follow up time reported and sufficient to be long enough 
for outcome to occur (minimum 6 months for this review) 
   
2. Was follow-up complete and if not, were the reasons to loss to 
follow up described and explored? 
   
3. Were strategies to address incomplete follow-up utilised (for 
example incidence expressed in person-years at risk?) 
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Legend of supplementary figures  
Supplementary figure 1: Summary of risk of bias assessment 
 
Supplementary figure 2. Prevalence of CrAg stratified by CrAg test used (Latex agglutination vs 
lateral flow assay) and study design (prospective, cross-sectional or retrospective). Abbreviations: 
ES, effect size; CI, confidence interval 
 
Supplementary figure 3. Prevalence of CrAg stratified by serum type (Fresh vs stored). 
Abbreviations: ES, effect size; CI, confidence interval 
 
Supplementary figure 4. Incidence of cryptococcal meningitis and all-cause mortality stratified by 
CrAg test used (Latex agglutination vs lateral flow assay). Abbreviations: M-H, Mantel-Haenszel; 
CI, confidence interval, LP, lumbar puncture 
 
References 
1. Meya DB, Manabe YC, Castelnuovo B, Cook BA, Elbireer AM, Kambugu A, et al. Cost-
effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-
infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in 
resource-limited settings. Clin Infect Dis 2010; 51(4): 448-55. 
 
